淺議馬庫什化合物權利要求的優先權問題  

On Issues Concerning Priority of Markush Compound Claims

作　　者：胡楊 任曉蘭 周劼聰 Hu Yang;Ren Xiaolan;Zhou Jiecong(Reexamination and Invalidation Department of the Patent Office,CNIPA;Patent Examination Cooperation(Jiangsu)Center of the Patent Uttice,CNIPA)

机构地区：[1]國家知識産權局專利局複審和無效審理部 [2]國家知識産權局專利局專利審查協作江蘇中心

出　　处：《中国专利与商标》2025年第1期20-28,共9页China Patents & Trademarks

摘　　要：引言一個新藥從研發到上市要經歷新化合物結構開發和篩選、生化試驗、動物試驗、臨床試驗等較長的週程,爲了搶佔先機保证其競争優勢,專利權入往往茌研發的早期,即化合物結構開發和篩選階段即申譆專利,實踐中也存在還末完成先導化合物篩選就申譆專利的情况。Introduction For a new drug,the journey from research and development to market usually takes a very long time,including new compound structure development and screening,biochemical tests,animal tests,clinical trials,etc.To get a firstmover advantage in competition,patentees tend to apply for patents in the early stage of research and development,i.e.,the phase of compound structure development and screening.In practice,it often occurs that patent applications go ahead of the completion of lead compound screening.

关 键 词：先导化合物 早期申请 马库什化合物 生化试验 

分 类 号：R95[医药卫生—药学]